NCT05783323 - Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 14, 2024

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2027

Conditions

Differentiated Thyroid CancerPediatric CancerCancerCancer, Thyroid

Interventions

DRUG

Larotrectinib monotherapy

Patients will receive larotrectinib monotherapy for 6 months at the FDA-approved dose.

RADIATION

131I therapy

Patients will receive 131I therapy after 6 months of larotrectinib.

Trial Locations (5)

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

RECRUITING

St. Jude Children's Research Hospital, Memphis

NOT_YET_RECRUITING

MD Anderson Cancer Center, Houston

RECRUITING

University of California, San Francisco, San Francisco

RECRUITING

Seattle Children's Hospital, Seattle